ALPHARETTA, GA / ACCESSWIRE / July 28, 2021 / RushNet, Inc (OTC PINK:RSHN), ('the Company') with its subsidiary heliosDX is pleased to announce Yann Gerville-Reache has been appointed to serve as the COO for heliosdX.

Mr. Gerville-Reache will join the Executive Team in Orange Park, FL to assume the role of Chief Operations Officer. His experience encompasses 20 years of operations within various industries including Transportation, Supply Chain, and the Energy sector. He brings his expertise supported by his certifications in lean manufacturing, project management, and supply chain management. With his diverse operational skillset, heliosDX will concentrate his efforts to support the setup and streamlining of people, processes, and systems which we believe will add significant value given his history in management at global corporations including CEVA Logistics (CMA CGM), Yusen Logistics (NYK), APR Energy (Atlas Corp), and through services and support of customers such as Nokia (formerly Alcatel Lucent), GSK, Medtronic, Nike, and other companies from various sectors.

Mr. Gerville-Reache officially assumes his role beginning August 2, 2021. We are extremely excited to have Mr. Gerville-Reache join the growing team at heliosDX. His expertise is needed and will be used immediately as he will be working directly on the National Sales/Branding System, Customer System Experience, as well as internal systems and operations.

About HeliosDx:

heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. Always staying ahead of the curve, by continually investing in our infrastructure with the most efficient scientific proven instruments, and latest cutting-edge software for patient and physician satisfaction. This allows heliosDX to provide physicians fast and accurate reporting meeting and exceeding industry benchmarks. We excel in patient and client care through physician designed panels that aid in testing compliance and reporting education.

CONTACT:
Ashley Sweat
asweat@heliosdx.com
www.heliosdx.com

Twitter Handle: @dx_helios

Safe Harbor Notice
Certain statements contained herein are 'forward-looking statements' (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment, or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: RushNet, Inc.